On 4 August 2026, Commissioner for Equality, Preparedness and Crisis Management, Hadja Lahbib, responding on behalf of the European Commission to a parliamentary question, declined to take a position on the scientific evidence concerning medical transition in minors, including the UK's Cass Review. The answer, to a question from MEPs Christine Anderson (ESN), Sebastian Kruis (PfE), and Marieke Ehlers (PfE), reiterates that healthcare policy, including clinical guidelines and evidence assessment, is a member state competence, and that the Commission has no position on related scientific reviews. This affects stakeholders including EU institutions, national health authorities, medical professionals, and advocacy groups on both sides of the debate.
The question, E-002509/2026, follows an earlier inquiry (E-000395/2026) that had remained unanswered for over four months, prompting the MEPs to press the Commission on whether it accepts, rejects, or partially accepts the Cass Review's conclusions on puberty blockers and cross-sex hormones for minors. The Commission's reply, however, does not engage with the scientific substance, instead restating the legal division of competences and referring to the expertise of EU agencies and scientific bodies within their mandates. The answer contains no concrete proposals, numerical targets, or deadlines, and offers no indication of when a substantive response might be provided.
the Commission frames the issue as outside its remit, thereby avoiding any direct endorsement or rejection of the Cass Review or any other evidence base. This approach may reassure member states that retain full control over clinical guidelines, but it leaves unanswered the question of which scientific sources inform EU policies that reference 'transgender youth'. Institutional follow-up is likely to be limited, as the Commission has signaled no intention to revisit the matter, though the MEPs may pursue further parliamentary scrutiny or seek a debate on the adequacy of the Commission's response.